8-K: PROCEPT BioRobotics Reports Strong 2023 Growth and Issues Positive 2024 Revenue Guidance

PROCEPT BioRobotics announced an 82% increase in full-year 2023 revenue and provided a 2024 revenue guidance of approximately $210 million.

Summary

• PROCEPT BioRobotics reported a significant increase in revenue for both the fourth quarter and full year 2023.
• Fourth-quarter revenue reached $43.6 million, an 83% increase compared to the same period in the previous year.
• Full-year 2023 revenue totaled $136.2 million, an 82% increase compared to 2022.
• The company's U.S. system and rental revenue for the fourth quarter was $16.6 million, a 59% increase year-over-year.
• U.S. handpiece and consumables revenue for the fourth quarter was $21.6 million, a 109% increase year-over-year.
• The install base of AquaBeam Robotic Systems in the U.S. reached 315 systems by the end of 2023.
• International revenue for the fourth quarter was $3.3 million, a 65% increase compared to the prior year period.
• Gross margin for the fourth quarter was 49%, impacted by approximately $2.5 million in costs related to manufacturing facility relocation and inventory adjustments.
• Operating expenses for the fourth quarter were $50.8 million, an increase from $35.7 million in the prior year period, due to commercial expansion and R&D investments.
• The net loss for the fourth quarter was $27.5 million, compared to a loss of $28.2 million in the prior year period.
• The company's full-year 2023 gross margin was 52%, compared to 49% in 2022.
• Operating expenses for the full year 2023 were $180.2 million, compared to $117.8 million in 2022.
• The net loss for the full year 2023 was $105.9 million, compared to a loss of $87.2 million in 2022.
• PROCEPT BioRobotics issued a 2024 revenue guidance of approximately $210 million, projecting a 54% growth over 2023.
• The company projects a full-year 2024 gross margin of approximately 57% to 59% and an adjusted EBITDA loss of approximately $73 million.

Sentiment

Score: 8

Explanation: The document presents a very positive outlook with strong revenue growth and positive future guidance, although there are some concerns about losses and increased operating expenses. The overall sentiment is optimistic.

Positives

• The company experienced substantial revenue growth in both the fourth quarter and full year 2023.
• There was a significant increase in U.S. system and handpiece revenue.
• The install base of AquaBeam Robotic Systems in the U.S. grew considerably.
• The company's average monthly utilization in the U.S. increased by approximately 10%.
• The company provided strong revenue guidance for 2024, projecting a 54% growth.
• Gross margin improved for the full year 2023 compared to 2022.
• The company is implementing remediation to address manufacturing issues and is already seeing improvements in the first quarter of 2024.

Negatives

• The company experienced a net loss for both the fourth quarter and full year 2023.
• Gross margin in the fourth quarter was negatively impacted by costs associated with the relocation of the manufacturing facility and corporate office.
• Operating expenses increased significantly due to commercial expansion and R&D investments.
• The company incurred an approximate 35% increase in scrap expense when producing units compared to the third quarter of 2023.
• Adjusted EBITDA was a loss for both the fourth quarter and full year 2023.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's ability to achieve its projected financial performance for 2024 is not guaranteed.
• The company's manufacturing issues and increased scrap expense could impact future profitability.
• The company's continued losses and negative adjusted EBITDA could raise concerns about its long-term financial sustainability.
• The company's reliance on the success of Aquablation therapy and the AquaBeam Robotic System exposes it to market and technological risks.

Future Outlook

The company projects revenue for the full year 2024 to be approximately $210 million, with a gross margin of approximately 57% to 59% and an adjusted EBITDA loss of approximately $73 million.

Management Comments

• Reza Zadno, Chief Executive Officer, stated that he is extremely proud of the company's commercial achievements in 2023.
• Management believes there are several positive factors that will enable the company to continue to pursue its long-term growth strategy while also demonstrating a disciplined approach on its path to profitability.
• Management believes the underlying fundamentals reflect a technology that is establishing the foundation to become the BPH surgical standard of care and a business poised to be a leading Urology company globally.

Industry Context

This announcement reflects the growing trend of robotic surgery in urology and the increasing adoption of minimally invasive procedures for BPH treatment. The company's strong revenue growth and positive guidance indicate a competitive position in the market.

Comparison to Industry Standards

• Intuitive Surgical, a leader in robotic surgery, reported a 12% increase in revenue for the full year 2023, while PROCEPT BioRobotics reported an 82% increase, indicating a much faster growth rate.
• Globally, the surgical robotics market is experiencing rapid growth, with a projected CAGR of over 10% in the coming years, suggesting that PROCEPT BioRobotics is well-positioned to capitalize on this trend.
• Compared to other medical device companies in the urology space, PROCEPT BioRobotics' revenue growth is significantly higher, suggesting a strong market acceptance of their Aquablation therapy.
• While some competitors focus on different surgical approaches for BPH, PROCEPT BioRobotics' robotic system offers a unique image-guided approach, which may provide a competitive advantage.

Stakeholder Impact

• Shareholders will likely react positively to the strong revenue growth and positive future guidance.
• Employees may benefit from the company's expansion and growth.
• Customers (hospitals and surgeons) will have access to an innovative surgical technology.
• Suppliers may see increased demand for their products and services.
• Creditors may view the company's growth positively, but will also be aware of the ongoing losses.

Next Steps

• The company will host a conference call to discuss the fourth quarter 2023 financial results.
• The company expects to file its annual report on Form 10-K with the SEC on or about February 28, 2024.
• The company will continue to focus on expanding its commercial organization and investing in research and development.

Key Dates

Keywords

PROCEPT BioRobotics, AquaBeam Robotic System, Aquablation therapy, urology, surgical robotics, BPH, revenue, gross margin, EBITDA, financial results, medical devices